Specific immunotherapy in atopic dermatitis

Acta Dermatovenerologica Croatica

Volumn 14, Issue 1, 2006, Pages 52-59

  Czarnecka Operacz, Magdalena ^a   Silny, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Airborne allergens; Atopic dermatitis; IgE; Specific immunotherapy

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOLOGIC AGENT;

AIRBORNE INFECTION; ATOPIC DERMATITIS; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MEDICAL RESEARCH; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW; VACCINATION;

DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; VACCINES;

EID: 33646035815     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Corbo GM, Ferrante E, Macciocci B, Foresi A, De Angelis V, Fabrizi G, et al. Bronchial hyperresponsiveness in atopic dermatitis.Allergy 1989;44:595.
2. Dohi M, Okudaira H, Sugiyama H, Tsurumachi K, Suko M, Nakagawa T, et al. Bronchial responsiveness to mite allergen in atopic dermatitis without asthma. Int Arch Allergy Appl Immunol 1990;92:138.
3. Fabrizi G, Corbo GM, Ferrante E, Macciocchi B, De Angelis V, Romano A, et al. The relationship between allergy, clinical symptoms and bronchial responsiveness in atopic dermatitis. Acta Derm Venereol 1992;176:68-73.
4. Salob SP, Laverty A, Atherton DJ. Bronchial hyper-responsiveness in children with atopic dermatitis. Pediatrics 1993;91:13.
5. Brinkman L, Aslander MM, Raaijmakers JA. Bronchial and cutaneous responses in atopic dermatitis patients after allergen inhalation challenge. Clin Exp Allergy 1997;27:1043.
6. Rajka G. Atopic dermatitis with special reference to the role of allergic factors. Acta Dermatol Venerol 1961;41:1-39.
7. Norris PG, Schofield B, Camp RDR. A study of the role of house dust mite in atopic dermatitis. Br J Dermatol 1988;118:435.
8. Mitchell EB, Crow J, Chapman MD, Jouhal SS, Pope FM, Platts-Mills TA. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1982;1:127-130.
9. Tanaka Y, Tanaka M, Anan S. Immunohistochemical studies on dust mite antigen in positive reaction site of patch test. Acta Dermatol Venerol 1989; 144:93.
10. Mitchel EB, Crow J, Williams G. Increase in skin mast cells following chronic house dust mite exposure. Br J Dermatol 1986;114:65-73.
11. Bruijnzeel-Koomem C, Van Wichen DF, Spry CJF. Active participation of eosinophiles in patch test reaction to inhalant allergens in patients with atopic dermatitis. Br J Dermatol 1988;118:229.
12. Allgust PJ. House dust mite causes atopic eczema. A preliminary study. Br J Dermatol 1984;3:10-11.
13. Beck HI, Korsgaard J. Atopic dermatitis and house dust mites. Acta Dermatol Venereol 1989;144:125.
14. Grewe M, Brujnzeel-Koomen CA, Schopf F, Thepen T, Langeveld-Wildschut AG, Ruzicka T, et al. A role of Th1 and Th2 cells in immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359.
15. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+Tcells from allergic individuals. J Exp Med 1993;178:2123.
16. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102:157.
17. Benjaponpitak S, Oro A, Maguire P. The kinetics of change in cytokine production by CD4+T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999;103:468.
18. Varney VA, Gaga M, Mavroleon G, Frew AJ. Usefulness of immunotherapy in patients with summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265.
19. Ortolani C, Pastorello E, Moss RB, Hsu YP, Restuccia M, Joppolo G, et al. Grass pollen immunotherapy: a single year double-blind, placebo controlled study in patients with grass pollen-induced asthma and rhinitis. J Allergy Clin Immunol 1984;73:283.
20. Bosquet J, Hejjaoui A, Skassa-Brociek W, Guerin B, Maasch HJ, Dhivert H, et al. Double-blind, placebo-controlled immunotherapy with mixed grass pollen allergoids. Rush immunotherapy with allergoids and standarized grass pollen extract. J Allergy Clin Immunol 1987;80:591.
21. Norman PS, Winkelwerder W, Lichtenstein L. Immunotherapy of hay fever with ragweed antigen E: comparisons with whole pollen extract and placebo. J Allergy 1968;42:93-108.
22. D'Amato G, Kordash TR, Liccardi G, Lobefalo G, Cazzola M, Freshwater LL. Immunotherapy with Alpare in patients with respiratory allergy to Parietaria pollen. A two-year double-blind placebo-controlled study. Clin Exp Allergy 1995; 25:149.
23. Bousguet J, Michel F B. Specific immunotherapy in asthma: is it effective? J Allergy Clin Immunol 1994;94:1-11.
24. Warner JO, Prince JF, Soothill JF, Hey EN. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978;24: 912.
25. Wahn U, Schweter C, Lind P, Lowenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite cultures and mite bodies. J Allergy Clin Immunol 1988;82:360.
26. Van Bever HP, Stevens WJ. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992;5: 318.
27. Pichler CE, Maquardsen A, Sparholt S, Lowenstein H, Bircher A, Bischof M. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchical hyperreactivity. Allergy 1997;52:274.
28. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amoido FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157.
29. Müller U, Helbling A, Berchtoled E. Immunotherapy with honey-bee venom and yellow-jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529.
30. Des Roches A, Paradis L, Menerado JL, Bouges S, Daures JP, Bosquet J. Immunotherapy with a standarized Dermatophagoides pteronyssinus extract. Specific immunotherapy prevents the onset of new sensitization in children. J. Allergy Clin Immunol 1997;99:450-453.
31. Jacobsen L, Dreborg S, Moller C. Immunotherapy as a preventive allergy treatment. J Allergy Clin Immunol 1996;97:232.
32. Strauss JS, Kligman A. The relationship between atopic allergy and dermatitis. Arch. of Dermatol 1957;75:806.
33. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo controlled study. Annals of Allergy 1974;32:321.
34. Di Prisco de Fuenmayor MC, Champion RH. Specific hyposensitization in atopic dermatitis. BrJ Dermatol 1979;101:697-707.
35. Austin VH. Atopic skin disease. If other treatments fail is hyposensitization the answer? Mod Vet Pract 1976;57:355.
36. Korossy S, Vincze E, Csizer Z, Juhasz V. Experiences with Bencard's specific "desensitizing" vaccine treatment in allergic skin diseases. Dermatol Monatsschr 1973;159:110.
37. Korossy S, Vincze E, Csizer Z, Juhasz V. Theory and practice of specific desensitization therapy of allergic skin diseases. Orv Hetil 1972;113:2579.
38. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982; 93: 597-602.
39. Zachariae H, Cramers M, Herlin T, Jensen J, Kragballe K, Ternowitz T, et al. Non-specific and specific hyposensitization in severe atopic dermatitis. Acta Derm Venerol 1985; 114:48-54.
40. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allerg 1992; 22:440.
41. Leroy BP, Boden G, Lachapelle JM, Jacquemin MG, Saint-Remy JM. A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind placebo-controlled study. J Am Acad Dermatol 1993; 28:232.
42. Mosca M, Albani-Rocchetti G, Vignini MA. La vaccinoterapia sub-linguale nella dermatite atopica. G Ital Dermatol Venereol 1993; 128:79-83.
43. Pacor ML, Biasi D, Malekina T. The efficacy of long-term specific immunotherapy for Dermatophagoides pteronyssinus in patients with atopic dermatitis. Recenti Prog. Med 1994; 85:273.
44. Galli E, Chini L, Nardi S, Benincori N, Panei P, Fraioli G. et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol 1994; 22: 18-22.
45. Zwacka G, Glaser S, Reiger B. Therapeutische Erfahrungen mit Pangramin-SLIT im verleich zu einer subkutaneum Immunotherapie und zur symptomatichen medicamentosen Behandlung bie Kindern mit Asthma bronchiale, Rhinoconjunctivitis und Atopischer dermatitis. Allergologie 1996;19:580.
46. Rudzki E, Litewska D, Samochocki Z. Sensitivity to the primary house dust allergen-dermatophagoides pteronyssinus-in patients with atopic dermatitis. Pol Tyg Lek 1990;45:880.
47. Samochocki Z, Rudzki E. Results of desensitization using household dust mite in patients with atopic dermatitis. Przegl Dermatol 1990; 77: 132.
48. Trofimowicz A, Rzepacka E, Hoffman J. Clinical effect of specific immunotherapy in children with atopic dermatitis. Rocz Akad Med Bialymst 1995;40:414.
49. Mastrandrea F: Immunotherapy in atopic dermatitis. Exp Opin Invest Drugs 2001;10: 49-63.
50. Bosquet J, Lockey RF, Mailing HJ. WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998;53:1-42.
51. Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis. Poznańskie Zakłady Graficzne SA,Poznań,2000.
52. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score. Wiad Lekarskie 2005;58:47-55.
53. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part II. Evaluation of skin reactivity and concentration of serum antigen specific immunoglobulin E against selected airborne allergens. Wiad Lekarskie 2005;58:184.
54. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part III. - in press.
55. Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis-results of double blind placebo controlled study - in press.